Shanthakumar Tyavanagimatt

1.1k total citations
19 papers, 806 citations indexed

About

Shanthakumar Tyavanagimatt is a scholar working on Molecular Biology, Virology and Epidemiology. According to data from OpenAlex, Shanthakumar Tyavanagimatt has authored 19 papers receiving a total of 806 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Molecular Biology, 10 papers in Virology and 10 papers in Epidemiology. Recurrent topics in Shanthakumar Tyavanagimatt's work include Herpesvirus Infections and Treatments (9 papers), Poxvirus research and outbreaks (9 papers) and Bacillus and Francisella bacterial research (8 papers). Shanthakumar Tyavanagimatt is often cited by papers focused on Herpesvirus Infections and Treatments (9 papers), Poxvirus research and outbreaks (9 papers) and Bacillus and Francisella bacterial research (8 papers). Shanthakumar Tyavanagimatt collaborates with scholars based in United States, United Kingdom and Italy. Shanthakumar Tyavanagimatt's co-authors include Dennis E. Hruby, Robert Jordan, Janet M. Leeds, Kevin F. Jones, Tové C. Bolken, Dongcheng Dai, Michael L. Corrado, Chelsea M. Byrd, Aklile Berhanu and Jarasvech Chinsangaram and has published in prestigious journals such as Blood, PLoS ONE and Antimicrobial Agents and Chemotherapy.

In The Last Decade

Shanthakumar Tyavanagimatt

18 papers receiving 739 citations

Peers

Countries citing papers authored by Shanthakumar Tyavanagimatt

Since Specialization

Citations

This map shows the geographic impact of Shanthakumar Tyavanagimatt's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shanthakumar Tyavanagimatt with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shanthakumar Tyavanagimatt more than expected).

Fields of papers citing papers by Shanthakumar Tyavanagimatt

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Shanthakumar Tyavanagimatt. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shanthakumar Tyavanagimatt. The network helps show where Shanthakumar Tyavanagimatt may publish in the future.

Co-authorship network of co-authors of Shanthakumar Tyavanagimatt

This figure shows the co-authorship network connecting the top 25 collaborators of Shanthakumar Tyavanagimatt. A scholar is included among the top collaborators of Shanthakumar Tyavanagimatt based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Shanthakumar Tyavanagimatt. Shanthakumar Tyavanagimatt is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

19 of 19 papers shown

#	Work	Indexed citations
1	Identification and Characterization of a Small Molecule Bcl-2 Functional Converter 2024 ·Cancer Research Communications ·Prasad Kopparapu, (unknown), Christiane V. Löhr, (unknown), Hyo Sang Jang, Shanthakumar Tyavanagimatt, Edmond F. O’Donnell, Harikrishna Nakshatri, Siva K. Kolluri	2
2	Small Molecule Functional Converter of B-Cell Lymphoma-2 (Bcl-2) Suppresses Breast Cancer Lung Metastasis 2024 ·ACS Pharmacology & Translational Science ·Prasad Kopparapu, Christiane V. Löhr, (unknown), Shanthakumar Tyavanagimatt, Harikrishna Nakshatri, Siva K. Kolluri	0
3	Pacritinib is a potent ACVR1 inhibitor with significant anemia benefit in patients with myelofibrosis 2023 ·Blood Advances ·Stephen T. Oh, Ruben A. Mesa, Claire Harrison, Prithviraj Bose, Aaron T. Gerds, Vikas Gupta, Bart L. Scott, Jean‐Jacques Kiladjian, Alessandro Lucchesi, Tim Kong, Sarah Buckley, Shanthakumar Tyavanagimatt, Bryan Harder, (unknown), Jennifer A. Smith, Adam R. Craig, John Mascarenhas, Srđan Verstovšek	39
4	Pacritinib Is a Potent ACVR1 Inhibitor with Significant Anemia Benefit in Patients with Myelofibrosis 2022 ·Blood ·Stephen T. Oh, Ruben A. Mesa, Claire Harrison, Prithviraj Bose, Aaron T. Gerds, Mark Heaney, Vikas Gupta, Bart L. Scott, Jean‐Jacques Kiladjian, Alessandro Lucchesi, Sarah Buckley, Shanthakumar Tyavanagimatt, (unknown), John Mascarenhas, Srđan Verstovšek	19
5	MPN-145 Retrospective Analysis of Anemia Benefit of Pacritinib From the PERSIST-2 Trial 2022 ·Clinical Lymphoma Myeloma & Leukemia ·Stephen T. Oh, Ruben A. Mesa, Claire Harrison, Prithviraj Bose, Aaron T. Gerds, Vikas Gupta, (unknown), Shanthakumar Tyavanagimatt, Sarah Buckley, (unknown), Srđan Verstovšek	7
6	Results of PAC203: A Randomized Phase 2 Dose-Finding Study and Determination of the Recommended Dose of Pacritinib 2019 ·Blood ·Aaron T. Gerds, Michael R. Savona, Bart L. Scott, Moshe Talpaz, Miklós Egyed, Claire Harrison, Abdulraheem Yacoub, Alessandro M. Vannucchi, Adam J. Mead, Jennifer O’Sullivan, Sarah Buckley, Diane R. Mould, Shanthakumar Tyavanagimatt, Jennifer A. Smith, John Mascarenhas	21
7	A potent Lassa virus antiviral targets an arenavirus virulence determinant 2018 ·PLoS Pathogens ·Ikenna G. Madu, Megan Files, Dima Gharaibeh, (unknown), (unknown), Brian B. Gowen, Dongcheng Dai, Kevin F. Jones, Shanthakumar Tyavanagimatt, (unknown), Marcus J. Korth, Kristin Bedard, Shawn P. Iadonato, Sean M. Amberg	44
8	Pharmacokinetics and Interspecies Allometric Scaling of ST-246, an Oral Antiviral Therapeutic for Treatment of Orthopoxvirus Infection 2013 ·PLoS ONE ·Adams Amantana, Yali Chen, Shanthakumar Tyavanagimatt, Kevin F. Jones, Robert Jordan, Jarasvech Chinsangaram, Tové C. Bolken, Janet M. Leeds, Dennis E. Hruby	9
9	Novel Benzoxazole Inhibitor of Dengue Virus Replication That Targets the NS3 Helicase 2013 ·Antimicrobial Agents and Chemotherapy ·Chelsea M. Byrd, Douglas W. Grosenbach, Aklile Berhanu, Dongcheng Dai, Kevin F. Jones, (unknown), Christine A. Schneider, Guang Yang, Shanthakumar Tyavanagimatt, (unknown), (unknown), Jessica Pagé, Eric Stavale, (unknown), (unknown), Candace Lovejoy, Janet M. Leeds, Dennis E. Hruby, Robert Jordan	82
10	SAR analysis of a series of acylthiourea derivatives possessing broad-spectrum antiviral activity 2012 ·Bioorganic & Medicinal Chemistry Letters ·(unknown), (unknown), Jordan Boutilier, (unknown), Dima Gharaibeh, Candace Lovejoy, Sean M. Amberg, Dennis E. Hruby, Shanthakumar Tyavanagimatt, Robert D. Allen, Dongcheng Dai	38
11	Pharmacokinetic and Pharmacodynamic Modeling To Determine the Dose of ST-246 To Protect against Smallpox in Humans 2012 ·Antimicrobial Agents and Chemotherapy ·Janet M. Leeds, (unknown), Nathalie Gosselin, Samer Mouksassi, Nastya Kassir, Jean‐Francois Marier, Yali Chen, (unknown), (unknown), Kady M. Honeychurch, Jarasvech Chinsangaram, Shanthakumar Tyavanagimatt, Dennis E. Hruby, Robert Jordan	19
12	A Novel Inhibitor of Dengue Virus Replication That Targets the Capsid Protein 2012 ·Antimicrobial Agents and Chemotherapy ·Chelsea M. Byrd, Dongcheng Dai, Douglas W. Grosenbach, Aklile Berhanu, Kevin F. Jones, (unknown), Christine A. Schneider, (unknown), Jessica Pagé, (unknown), Eric Stavale, Shanthakumar Tyavanagimatt, (unknown), Ralf Bartenschlager, Pietro Scaturro, Dennis E. Hruby, Robert Jordan	136
13	Pharmacokinetic Comparison of a Single Oral Dose of Polymorph Form I versus Form V Capsules of the Antiorthopoxvirus Compound ST-246 in Human Volunteers 2012 ·Antimicrobial Agents and Chemotherapy ·Jarasvech Chinsangaram, Kady M. Honeychurch, Shanthakumar Tyavanagimatt, Tové C. Bolken, Robert Jordan, Kevin F. Jones, Thomas Marbury, (unknown), (unknown), Michael L. Corrado, (unknown), (unknown), (unknown), Dennis E. Hruby	15
14	Safety and Pharmacokinetics of the Anti-Orthopoxvirus Compound ST-246 following a Single Daily Oral Dose for 14 Days in Human Volunteers 2012 ·Antimicrobial Agents and Chemotherapy ·Jarasvech Chinsangaram, Kady M. Honeychurch, Shanthakumar Tyavanagimatt, Janet M. Leeds, Tové C. Bolken, Kevin F. Jones, Robert Jordan, Thomas Marbury, Jon Ruckle, (unknown), Eric A. Ross, (unknown), (unknown), Michael L. Corrado, (unknown), (unknown), Dennis E. Hruby	46
15	Safety and Pharmacokinetics of the Antiorthopoxvirus Compound ST-246 following Repeat Oral Dosing in Healthy Adult Subjects 2010 ·Antimicrobial Agents and Chemotherapy ·Robert Jordan, Jarasvech Chinsangaram, Tové C. Bolken, Shanthakumar Tyavanagimatt, Deborah Tien, Kevin F. Jones, (unknown), Michael L. Corrado, (unknown), (unknown), (unknown), Thomas Marbury, Dennis E. Hruby	41
16	Development of ST-246® for Treatment of Poxvirus Infections 2010 ·Viruses ·Robert Jordan, Janet M. Leeds, Shanthakumar Tyavanagimatt, Dennis E. Hruby	92
17	ST-246 Antiviral Efficacy in a Nonhuman Primate Monkeypox Model: Determination of the Minimal Effective Dose and Human Dose Justification 2009 ·Antimicrobial Agents and Chemotherapy ·Robert Jordan, Arthur J. Goff, (unknown), Michael L. Corrado, Lisa E. Hensley, Chelsea M. Byrd, Eric M. Mucker, (unknown), Tové C. Bolken, Carly Wlazlowski, Wendy Johnson, Jennifer Chapman, Nancy Twenhafel, Shanthakumar Tyavanagimatt, Adams Amantana, Jarasvech Chinsangaram, Dennis E. Hruby, John W. Huggins	108
18	Immune responses to the smallpox vaccine given in combination with ST-246, a small-molecule inhibitor of poxvirus dissemination 2008 ·Vaccine ·Douglas W. Grosenbach, Robert Jordan, David S. King, Aklile Berhanu, Travis K. Warren, (unknown), Shanthakumar Tyavanagimatt, Ying Tan, Rebecca L. Wilson, Kevin F. Jones, Dennis E. Hruby	26
19	Single-Dose Safety and Pharmacokinetics of ST-246, a Novel Orthopoxvirus Egress Inhibitor 2008 ·Antimicrobial Agents and Chemotherapy ·Robert Jordan, Deborah Tien, Tové C. Bolken, Kevin F. Jones, Shanthakumar Tyavanagimatt, Josef Strasser, (unknown), Michael L. Corrado, (unknown), Dennis E. Hruby	62

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact